AllDayGLP
1mg
ALG-B2024-008
≥99%
IGF-1 LR3 Research Vial 1mg
$89.99
Batch: ALG-B2024-008
Store lyophilized at -20°C or 2-8°C. Reconstituted solution: store at 2-8°C, use within protocol timeframe.
IGF-1 LR3 is a modified insulin-like growth factor 1 analogue featuring enhanced bioavailability and extended half-life via the Long R3 modification. Designed for research into muscle cell proliferation, protein synthesis signaling, and growth factor biology.
For research or professional use only, where legally permitted. Not intended to diagnose, treat, cure, or prevent any disease.
IGF-1 LR3 (Insulin-Like Growth Factor-1 Long R3) is a genetically modified analogue of the native IGF-1 peptide, engineered to exhibit superior pharmacokinetic and pharmacodynamic properties. The Long R3 modification consists of a 13-amino-acid extension at the N-terminus combined with an arginine substitution at position 3. This structural alteration significantly reduces binding affinity to all six IGF binding proteins (IGFBPs), resulting in increased concentrations of free, bioactive peptide available for receptor activation. **Mechanism of Action:** IGF-1 LR3 exerts its effects primarily through activation of the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor. Ligand binding initiates downstream signaling cascades including the PI3K/Akt pathway — promoting cell survival and anti-apoptotic signaling — and the MAPK/ERK pathway — driving cell proliferation and differentiation. In research models, IGF-1 LR3 demonstrates particular potency in promoting satellite cell activation, myogenic differentiation, and muscle fiber hypertrophy. At higher concentrations, insulin-like metabolic effects may be observed due to cross-reactivity with the insulin receptor. **Research Applications:** With 10 PubMed-verified studies, IGF-1 LR3 is among the most studied modified growth factor analogues. Laboratory research applications include: investigations into muscle protein synthesis and hypertrophy signaling cascades; studies of satellite cell activation and myonuclear accretion in skeletal muscle models; exploration of anti-apoptotic signaling in tissue regeneration models; and examinations of the IGF-1/GH axis in growth and development research. The extended half-life of approximately 20-30 hours (versus 12-15 hours for native IGF-1) enables once-daily dosing in research protocols. **Quality Documentation:** Each lot is manufactured under controlled laboratory conditions. Purity is verified at ≥99% by HPLC analysis. Each vial contains 1mg of lyophilized IGF-1 LR3 peptide. Reconstitute with bacteriostatic water or sterile water for research use. Batch-specific certificates of analysis and mass spectrometry data are available upon request. This product is intended for laboratory research purposes only and is not for human or veterinary use. Note: IGF-1 LR3 is listed on the WADA Prohibited List.
